Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes

Rationale: Increasing frequency of human exposure to PEG-related products means that healthy people are likely to have pre-existing anti-PEG antibodies (pre-αPEG Ab). However, the influence of pre-αPEG Abs on the pharmacokinetics (PK) and therapeutic efficacy of LipoDox is unknown. Methods: We gener...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Theranostics
Main Authors: Hsieh, Yuan-Chin, Wang, Hsin-Ell, Lin, Wen-Wei, Roffler, Steve R., Cheng, Ta-Chun, Su, Yu-Cheng, Li, Jia-Je, Chen, Chao-Cheng, Huang, Chun-Han, Chen, Bing-Mae, Wang, Jaw-Yuan, Cheng, Tian-Lu, Chen, Fang-Ming
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5996368/
https://ncbi.nlm.nih.gov/pubmed/29896310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.22164
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados